Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 14, 2024; 30(42): 4576-4582
Published online Nov 14, 2024. doi: 10.3748/wjg.v30.i42.4576
Published online Nov 14, 2024. doi: 10.3748/wjg.v30.i42.4576
Metabolic dysfunction-associated steatotic liver disease: The question of long-term high-normal alanine aminotransferase as a screening test
Terence N Moyana, Department of Pathology and Laboratory Medicine, University of Ottawa and The Ottawa Hospital, Ottawa K1H 8L6, Ontario, Canada
Author contributions: As the sole author, Moyana TN is responsible for all aspects of the work, including conception, design, research, writing, and finalization of the manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Terence N Moyana, FRCPC, MD, Full Professor, Department of Patho logy and Laboratory Medicine, University of Ottawa and The Ottawa Hospital, 501 Smyth Road, General Campus, Ottawa K1H 8L6, Ontario, Canada. tmoyana@eorla.ca
Received: July 17, 2024
Revised: September 26, 2024
Accepted: October 9, 2024
Published online: November 14, 2024
Processing time: 105 Days and 10.8 Hours
Revised: September 26, 2024
Accepted: October 9, 2024
Published online: November 14, 2024
Processing time: 105 Days and 10.8 Hours
Core Tip
Core Tip: High normal alanine aminotransferase (ALT) has potential utility in screening for new-onset metabolic dys